Jon Napitupulu

Novo Nordisk has agreed to acquire Akero Therapeutics for up to $5.2 billion in cash, adding the FGF21 analogue...

Digital Utilities Ventures, operating as Easy Environmental Solutions, has completed FINRA’s corporate action process, finalizing its acquisition of Lifestyle...

Catalyst Pharmaceuticals will present new real-world evidence across Duchenne muscular dystrophy and Lambert-Eaton myasthenic syndrome at major neuromuscular meetings...

Pelthos Therapeutics has launched “Moms Against Molluscum,” a caregiver-focused movement and website designed to elevate awareness of molluscum contagiosum...

Beghou has launched ARC, a connected commercialization platform designed to unify data, technology, and field execution into a single...

Gelteq has signed a product development and profit‑sharing agreement with Melbourne Health, operator of the Royal Melbourne Hospital, to...

Rein Therapeutics has secured authorization from the European Medicines Agency to initiate the Phase 2 RENEW trial of LTI-03...

Assembly Biosciences reported interim Phase 1b results for its long-acting HSV helicase-primase inhibitor ABI-5366, presented as a late-breaking oral...

60 Degrees Pharmaceuticals will initiate B-FREE, a Phase 2 open-label study of tafenoquine (marketed as Arakoda for malaria prophylaxis)...

FDA has approved Lasix Onyu, a subcutaneous, high‑concentration furosemide drug–device combination for treating edema due to fluid overload in...